Diabetic nephropathy in non-insulin dependent diabetes mellitus: Cardiovascular risk factors and antihypertensive treatment

Danish Medical Bulletin

Volumn 47, Issue 4, 2000, Pages 249-270

  Nielsen, F S ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; HEART LEFT VENTRICLE FUNCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CLINICAL TRIALS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMAN; HYPERTENSION; KIDNEY; LIPOPROTEIN(A); MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033806977     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (301)

1. Renal replacement therapy in the united states: Data from the United States renal data system
2. Problems related to definitions and epidemiology of Type 2 (non-insulin-dependent) diabetes mellitus: Studies throughout the world
3. Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction
4. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer
5. Melatonin. Claims made in a popular media are mostly nonsense
6. Experimental diabetic cardiomyopathy preventable by insulin treatment
7. Neural and non-neural mechanisms influencing circulation during sleep
8. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection
9. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
10. Epidemiology of persistent proteinuria in Type II diabetes mellitus. Population-based study in Rochester, Minnesota
11. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy
12. Plasma disappearance of glycated and non-glycated albumin in Type 1 (insulin-dependent) diabetes mellitus: Evidence for charge dependent alterations of the plasma to lymph pathway
13. A new serum type system in man: The Lp system
14. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson)
15. Lipids, diabetes, and vascular disease: The time to act
16. Unilateral nodular diabetic glomerulosclerosis: Recurrence of an experiment of nature
17. Isolated office hypertension: A prehypertensive state?
18. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus
19. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
20. Renal protective effect of enalapril in diabetic nephropathy
21. Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism
22. The electro-cardiogram in population studies: A classification system
23. Blood pressure measurement section of the Deutche Liga zur Bekampfung des hohen Blutdruckes e.V.(German Hypertension League) Statement on ambulatory blood pressure monitoring by the German Hypertension League
24. Factor-VIII complex and endothelial damage
25. Serum melatonin response to melatonin administration in the Syrian hamster
26. 51Cr-EDTA
27. A simple method for the determination of glomerular filtration rate
28. Selection of routine method for determination of glomerular filtration rate in adult patients
29. Office hypertension in type 2 (non-insulin-dependent) diabetic patients
30. Renal sodium handling in patients with untreated hypertension and white coat hypertension
31. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
32. Psychophysiological reactivity and cardiac end-organ damage in white coat hypertension
33. Elektronisk blodtryksmaling
34. Digital systolic pressures in the lower limb in arterial disease
35. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis
36. Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy
37. Glomerulonephritis in diabetic patients and its effect on the prognosis
38. Rapid screening PEG radioimmunoassay for quantification of pathological microalbuminuria
39. Cerebrospinal fluid adrenalin and noradrenalin in depressed patients
40. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes
41. Diabetic cardiopathy: Is it a real entity?
42. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus
43. Effect of measuring ambulatory blood pressure on sleep and on blood pressure during sleep
44. Diabetic nephropathy. A clinical and morphometric study
45. Albuminuria reflects widespread vascular damage. The Steno hypothesis
46. Sleep apnea causes daytime hypertension
47. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension
48. Standardization of M-mode echocardiographic left ventricular anatomic measurements
49. Relation of reninangiotensin system to left ventricular hypertrophy and function in experimental and human hypertension
50. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method
51. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease
52. C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus
53. The kidney in maturity onset diabetes mellitus: A clinical study of 510 patients
54. Reversibility of diabetic cardiomyopathy with insulin in rabbits
55. Enzyme immunoassay: An improved determination of urinary albumin in diabetics with incipient nephropathy
56. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus
57. Microalbuminuria and clinical nephropathy in type 1 (insulin-dependent) diabetes mellitus: Pathophysiological mechanisms and intervention studies
58. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetics: Prevalence of impaired diurnal blood pressure patterns
59. High plasma prorenin in diabetes mellitus and its correlation with some complications
60. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation
61. Diabetic cystopathy
62. The heart in hypertension
63. Regional myocardial volume alterations induced by brief repeated coronary occlusion in conscious dogs
64. Epidemiology of hypentension in diabetic patients and implications for treatment
65. Circadian changes in vascular sympathetic activity in ambuiant subjects
66. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects
67. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham heart study)
68. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients
69. Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy
70. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
71. Albuminuria and poor glycemic control predict mortality in NIDDM
72. Heterogeneous nature of renal lesions in Type 11 diabetes
73. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension
74. The prognosic role of left ventricular hypertrophy in patients with or without coronary artery disease
75. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic: Renal diasease: A meta-analysis of randomized trials
76. Fasting plasma C-peptide, glucagon stimulated C-peptide, and urinary C-peptide in relation to clinical type of diabetes
77. Workshop on the use of renal biopsy in research on diabetic nephropathy: A summary report
78. White-coat hypertension as a cause of cardiovascular dysfunction
79. Effects of acute changes in blood glucose on HbA1c
80. Relation of left ventricular shape, function and wall stress in man
81. Non-insulin-dependent diabetes and renal replacement therapy
82. Left ventricular mass in diabetes-hypertension
83. Lipoprotein(a) in non-insulin-dependent diabetic patinets with normo-and microalbuminuria
84. Lipoprotein(a) in diabetic patients with and without chronic renal failure
85. Lp(a) concentrations in NIDDM
86. Lack of change of lipo-protein(a) concentration with improved glycaemic control in subjects with Type Il diabetes
87. Cardiovascular risk factors in non-insulin dependent diabetic subjects with microalbuminuria
88. Diabetic cardiomyopathy
89. Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy
90. Kidney function alter withdrawal of long-term antihypertensive treatment in diabetic nephropathy
91. Ambulatory blood pressure. Measurement in type 2 diabetic patients: Methodological aspects
92. Ambulatory blood pressure in microalbuminuric type 1 diabetic patients
93. Circadian variation of blood pressure in patients with diabetic nephropathy
94. Diurnal blood pressure variations in normoalbuminuric type 1 diabetic patients
95. How should circadian blood pressure variation be determined?
96. Loss of the nocturnal dip and increased variability of blood pressure in normotensive patients with non insulin-dependent diabetes mellitus
97. Effect of metabolic factors and blood pressure on kidney function in proteinuric Type 2 (non-insulin-dependent) diabetic patients
98. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes
99. Serum lipoprotein(a) in patients with diabetes mellitus
100. Relationship between lipoprotein(a) phenotypes and albumin excretion rate in non-insulin-dependent diabetes mellitus: Protective effect of 'null' phenotype
101. Elevation of von Willebrand factor levels in patients with IgA nephropathy: Effect of ACE inhibition
102. Decreased sympathetic vasomotor tone in diabetic orthostatic hypotension
103. A simple test for autonomic neuropathy in juvenile diabetics
104. Serum lipoprotein(a) concentrations and lipoprotein(a) phenotypes in the families of NIDDM patients
105. On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy
106. Ambulatory blood pressure and heart rate in diabetic patients: An assessment of autonomic function
107. Glomerular hemodynamics in experimental diabetes mellitus
108. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
109. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables
110. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus
111. Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: A population-based study
112. A sensitive ELISA for von Willebrand factor (vWF: Ag)
113. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy
114. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension
115. Pathophysiology of microvascular disease in non-insulin-dependent diabetes
116. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
117. Plasma apolipoprotein(a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
118. Long-term smoking increases transcapillary escape rate of albumin
119. Effects of indomethacin on glomerular hemodynamics in experimental diabetes
120. Increased plasma concentration of von Willebrand factor in insulin-dependent diabetic patients with incipient nephropathy
121. Metoprolol minimizes nighttime blood pressure dip hypertensive black males
122. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham Study
123. Blood pressure as a cardiovascular risk factor
124. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
125. Diurnal blood pressure profile in patients with severe congestive heart failure: Dippers and non-dippers
126. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease
127. Multicenter study of a new enzymatic method of cholesterol determination
128. What's in a name? IDDM/NIDDM, Type1/Type2
129. Renin - From beginning to end
130. Intercapillary lesions in the glomeruli of the kidney
131. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability
132. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects
133. NIDDM and its metabolic control predicts coronary heart disease in elderly subjects
134. Is white coat hypertension innocent? Structure and function of the heart in the elderly
135. Filtration as the main mechanism of overall transcapillary protein escape from the plasma
136. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
137. Arterial procollagen type I, type III, and fibronectin effects of diabetic serum glucose, insulin, ketone and growth hormone studied on rabbit aortic myomedial cell cultures
138. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study
139. Assessing the progression of renal disease in clinical studies: Effects of duration of follow-up and regression to the mean
140. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors
141. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham study
142. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
143. 135I-labelled hippuran
144. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications
145. The endothelium as a target and mediator of cardiovascular disease
146. Practical clinical value of the C-peptide response to glucagon stimulation in the choise of treatment in diabetes mellitus
147. Effects of blood pressure measurement by the doctor on patient's blood pressure and heart rate
148. Cardiovascular regulation during sleep
149. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study
150. Recent advances: Diabetes
151. Circadian variation of blood pressure in autonomic failure
152. Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites
153. Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes
154. Heart rate varlability in diabetes: Relationship to age and duration of the disease
155. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
156. Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients
157. Racial differences in cardiac structure and function in essential hypertension
158. Clinical and hemodynamic determinants of left ventricular dimensions
159. Nocturnal blood pressure in normotensive subjects and those with white coat, primary, and secondary hypertension
160. Prevalence on unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus
161. A potential basis for the thrombotic risk associated with lipoprotein(a)
162. Effects of dietary protein restriction on the progression of moderate renal disease in the modification of diet in renal disease study
163. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment
164. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
165. Microalbuminuria: An early marker of renal involvement in diabetes
166. Combined high blood pressure and glucose in type 2 diabetes: Double jeopardy
167. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy
168. Latent overhydration and nocturnal hypertension in diabetic nephropathy
169. Impaired left ventricular systolic function during exercise in middle-aged insulin-dependent and noninsulin-dependent diabetic subjects with and without clinically evident cardiovascular disease
170. Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients
171. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as jugded by treadmill exercise testing and coronary angiography
172. Circadian rhythm of blood pressure in normotesive NIDDM subjects. Its relationship to microvascular complications
173. Alteration of lipoprotein(a) concentration with glycaemic control in non-insulin-dependent diabetic subjects without diabetic complications
174. Transcapillary excape rate of albumin in type II diabetic patients
175. Oxidative modification of lipoprotein(a) and the effect of β-carotene
176. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
177. Effect of proteinuria on mortality in NIDDM
178. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus
179. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy
180. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
181. On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy
182. Left ventricular hypertrophy in non-insulin dependent diabetic patients with and without diabetic nephropathy
183. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy
184. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
185. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy
186. Impact of ramipril on left ventricular hypertrophy in normotensive non-albuminuric NIDDM patients
187. Increased sympathetic activity during sleep and nocturnal hypertension in NIDDM patients with diabetic nephropathy
188. The measurement of digital systolic blood pressure by strain gauge technique
189. Reduction of serum lipoprotein(a) levels in hyperlipideamic patients with α-tocopheryl nicotinate
190. State of the market. A review of ambulatory blood pressure monitoring devices
191. Heart rate variablity in healthy subjects: Effect of age and the derivation of normal ranges for tests of autonomic function
192. Lipids and Ip(a) lipoprotein level and coronary-artery disease in subjects with non-insulin-dependent diabetes-mellitus
193. Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population
194. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability
195. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension
196. Microvascular permeability to plasma proteins in hypertension and diabetes mellitus in man - On the pathogenesis of hypertensive and diabetic microangiopathy
197. Intravenous insulin has no effect on transcapillary escape rate of albumin and on plasma volume in short-term juvenile diabetics
198. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy
199. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
200. Hemodynamic factors in the genesis of diabetic microangiopathy
201. Reduced transcapillary escape rate of albumin during acute blood pressure-lowering in type 1 (insulin-dependent) diabetic patients with nephropathy
202. Effect of antihypertensive treatment on kidney function in diabetic nephropathy
203. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy
204. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus
205. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients
206. The course of kidney function in albuminuric non-insulin-dependent diabetic (NIDDM) patients with diabetic or non-diabetic glomerulopathy
207. Concentrations of von Willebrand factor in diabetes
208. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy
209. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy
210. Transcapillary escape rate of albumin and plasma volume in essential hypertension
211. Prognosis in diabetic nephropathy
212. The use of antihypertensive agents in prevention and treatment af diabetic nephropathy
213. Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy
214. Left ventricular mass in coronary artery disease without hypertension
215. Improved endothelial function with angiotensin-converting enzyme inhibitors
216. How should the diurnal changes of blood pressure be expressed?
217. White coat hypertension
218. How common is white coat hypertension?
219. Recommendations for the use of home (self) and ambulatory blood pressure monitoring
220. Von Willebrand factor as an indicator of endothelial cell dysfunction in diabetic microangiopathy: Studies in vivo
221. The epidemiology of diabetic nephropathy
222. Antihypertensive treatment efficacy in type II diabetes mellitus. Dissociation between causal and 24-hour ambulatory blood pressure
223. Diabetes and atherosclerosis: An epidemiological view
224. Circadian rhythms in cardiovascular disease
225. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size
226. Hypothesis: Lipoprotein(a) is a surrogate for ascorbate
227. Mortality in diabetic patients with cardiovascular autonomic neuropathy
228. Loss of nocturnal decline in blood pressure after cardiac transplantation
229. Non invasive determination of left ventricular end-systolic stress: Validation of the method and initial application
230. Recovery from decompensated non-insulin-dependent diabetes mellitus: Studies of C-peptide secretion
231. Increased prevalence of renal biopsy findings other than diabetic glomerulopathy in type II diabetes mellitus
232. Lipoprotein(a) in diabetes mellitus
233. Diabetic nephropathy in type II diabetes
234. Cardiovascular survey methods
235. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients
236. Monitoring kidney function in diabetic nephropathy
237. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes
238. Apolipoprotein(a) levels in type 1 and type 2 diabetes mellitus
239. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease
240. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
241. Association between left ventricular hypertrophy and erythrocyte sodium-lithium exchange in normotensive subjects with and without NIDDM
242. Captopril reduces nailfold capillary pressure in type 1 diabetic patients with established nephropathy
243. Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control
244. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham study
245. Cardiomyopathy associated with noninsulin-dependent diabetes
246. Lipoprotein(a) levels in african-americans with NIDDM
247. 24-Stunden-blutdruckmessung bei typ-2-diabetikern mit und ohne nephropathie
248. Dietary salt intake. A determinant of cardiac involvement in essential hypertension
249. Blood pressure by 24 h ambulatory recordings in type 2 (non-insulin dependent) diabetics. Relationship to urinary albumin excretion
250. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients
251. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
252. Prospective study of heart disease in untreated maturity onset diabetics
253. Limitations of creatinine as a filtration marker in glomerulopathic patients
254. Capillary pressure is reduced by ramipril in type 1 diabetic patients with microalbuminuria
255. Capillary pressure in patients with N1DDM
256. Effect of insulin on renal sodium handling in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance
257. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease
258. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients
259. Reference values for ambulatory blood pressure: A meta analysis
260. What is a normal blood pressure on ambulatory monitoring
261. Nocturnal blood pressure fall on ambulatory monitoring in a large internalional database
262. Von Willebrand factor and development of diabetic nephropathy in IDDM
263. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus
264. Urinary albumin excretion and cardiovascular disease risk in diabetes mellitus: Is endothelial dysfunction the missing link?
265. Lipoprotein Lp(a) excess and coronary heart disaese
266. Smootning twenty-four-hour ambulatory blood pressure profiles: A comparison of alternative methods
267. A clinical-histological study of individuals with diabetes mellitus and proteinuria
268. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V
269. Increased plasma apolipoprotein(a) levels in IDDM patients with diabetic nephropathy
270. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
271. Consensus document on non-invasive ambulatory blood pressure monitoring
272. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor
273. Rate of decline of glomerular filtration rate (GFR) in non-insulin dependent diabetic patients (NIDDs) with clinical proteinuria
274. Albuminuira and associated medical risk factors: A cross-sectional study in 451 type II (noninsulin-dependent) diabetic patients. Part 2
275. Effect of Pravastatin on serum lipids, apoliproteins and lipo-protein(a) in patients with non-insulin dependent diabetes mellitus
276. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus
277. Glomerular hyperfiltration in microalbuminuric N1DDM patients
278. Lipoprotein(a) in diabetic patinets and normoglycaemic relatives in familial NIDDM
279. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension
280. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events
281. Ambulatory blood pressure: An independent predictor of prognosis in essential hypertension
282. Ambulatory blood pressure and risk of cardiovascular disease in Type I diabetes mellitus
283. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass
284. Prognostic significance of the white coat effect
285. Monitoring glomerular function in diabetic nephropathy
286. Guidelines for the prevention of diabetic renal failure
287. Noninvasive automatic blood pressure monitoring does not attenuate nighttime hypotension. Evidence from 24 h intraarterial blood pressure monitoring
288. Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients
289. Human diabetic proteinuria is affected differently by ACE-inhibitors, calcium antagonists or conventional therapy
290. A multicenter evaluation of the AandD TM-2420 ambulatory blood pressure recorder
291. Diabetes mellitus
292. Reflex control of heart rate in normal subjects in relation to age: A data base for cardiac vagal neuropathy
293. Apolipoprotein(a) and ischaemic heart disease in familial hyper-cholesterolaemia
294. Capillary hypertension and abnormal pressure dynamics in patients with essential hypertension
295. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus
296. Lipoprotein(a) levels and diabetes control
297. Improved blood glucose control by insulin therapy in Type 2 diabetic patients has no effect on lipoprotein(a) levels
298. Carotid atheroslerosis and serum lipoprotein(a) concentrations in patients with NIDDM
299. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
300. Classification and diagnosis of diabetes mellitus